Estrella ImmunopharmaESLA
13F holders, Q1 2026 (March 31)16holders +1
6new positions
6sold out
1famous investor
$1.06avg. 13F price*
At the end of Q1 2026, 16 institutions reported holding Estrella Immunopharma Inc. (ESLA) in their 13F filings, up 1 from Q4 2025. 6 opened new positions and 6 sold out. The largest holders were Armistice Capital, LLC ($4.3M), Vanguard Capital Management LLC ($405K) and Wells Fargo & Company ($280K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Estrella Immunopharma Inc.
- CUSIP
- 297584104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $4.6M |
| Exits | 6 | $325K |
All 13F filers, Q4 2025 → Q1 2026: 4,459,697 shares bought and 279,103 shares sold, net +4,180,594 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Armistice Capital, LLC | 0.14% | New | 4,099,000 | $4.3M |
| Vanguard Capital Management LLC | 0.00% | — | 382,469 | $405K |
| Wells Fargo & Company | 0.00% | New | 264,388 | $280K |
| Geode Capital Management, LLC | 0.00% | Add +43.4% | 157,485 | $167K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 64,921 | $69K |
| Renaissance Technologies | 0.00% | Reduce -48.7% | 62,795 | $67K |
| State Street Corp. | 0.00% | No change | 43,252 | $46K |
| BlackRock, Inc. | 0.00% | Add +50.7% | 39,890 | $42K |
| Northern Trust Corp. | 0.00% | No change | 19,624 | $21K |
| US Bancorp \de | 0.00% | New | 16,904 | $18K |
| UBS Group AG | 0.00% | Add +373.1% | 15,079 | $16K |
| Royal Bank of Canada | 0.00% | No change | 6,600 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 4,859 | $5K |
| Toronto Dominion Bank | 0.00% | New | 1,089 | $1K |
| Wolverine Asset Management LLC | 0.00% | New | 468 | $496 |
| Morgan Stanley | 0.00% | Reduce -100.0% | 1 | $1 |
"% of holder's portfolio" is ESLA's weight in each manager's 13F, not the share of Estrella Immunopharma Inc. the manager owns.